Transcripta Bio

🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟 transcriptabio.com/post/mastering…

As part of @Nature’s @bpdealmakers, Transcripta Bio was featured for its pioneering work in AI-powered innovation for drug discovery. #TranscriptaBio #Biopharmadealmakers #Innovation nature.com/articles/d4374…

We are continuously exploring and building tools like MolSifter to map the relationships between chemical structure and gene expression to discover powerful new therapies for patients.

We've been using NVIDIA's MolMIM model — guided by our own perturbation predictions — to generate molecules with specific effects on gene expression. LLMs help by 1) orienting us to interesting patterns in a collection and 2) enabling chat-based analysis to gain deeper insight.

Characterizing collections of molecules is an important chemoinformatics task. Beyond annotating molecules by common descriptors, can we gain insight by leveraging LLMs for initial triage? Our prototype app, MolSifter, does just that!

We were honored to invite @ashleevance to Transcripta Bio to share our story and how we are charting a faster path in drug discovery to create better lives for people around the world. bloomberg.com/news/articles/…

Our Director of Software Engineering, Clayton Mellina, believes a patient-centered approach, coupled with breakthrough technologies in machine learning and high-throughput biology, will drive a revolution in human health. Read more of our conversation: rarebase.org/post/unleashin…

Rarebase has generated a premier drug screening dataset that maximizes efficiency in drug hunting for rare neurological diseases. Learn more about our breakthrough approach to meet the urgent needs of the #raredisease patient community: rarebase.org/post/how-the-r…

In our latest podcast, Director of High Throughput Biology, Joe Bellucci, PhD, walks us through advances in high-throughput screening and next-generation sequencing that have enabled tailored and scalable approaches to rare disease research. Listen here: spotifyanchor-web.app.link/e/4QnJYQo3nyb

Neurodevelopmental disorders make up 77% of our current drug discovery portfolio. This National Developmental Disabilities Awareness Month, let's champion support & inclusion for affected individuals with the rare disease community. #DDAM2023

Join us in recognizing #CACNA1A Awareness Day on March 19th! At Rarebase, we partner with the patient organization Miren's Marathon at the Rare Village Foundation in support of those affected by CACNA1A-related conditions. Together, we build a path forward for rare diseases.

Our discovery research team has been gearing up for compound testing in our Preclinical Stage! Our wild-type stem cells are thawed and ready for expansion and differentiation into neurons for concentration-response studies with Function-identified drug repurposing candidates.

We sat down with our Scientific Founder and Advisor, Elizabeth Iorns, PhD, to dive into the science and technology behind the Rarebase drug discovery strategy. Read more here: rarebase.org/post/reimagini…

At Rarebase, we are filling the void in rare disease drug discovery to meet the urgent unmet needs of the rare disease community. This #RareDiseaseDay, learn how our precision medicine platform is advancing the hunt for new therapies: rarebase.org/post/3-700-dis…

We are committed to making a difference in the lives of those affected by rare diseases and we look forward to supporting #RareDiseaseDay next week. Sign up for our newsletter to follow our journey: eepurl.com/hKNGWr

Tomorrow is International Day of Women and Girls in Science 🧬🔬🚀 We are grateful to all the women on the Rarebase team for your tireless work to foster partnerships with patient organizations and drive our precision medicine research forward for the #raredisease community.

Honored to be working with @cureSYNGAP1 on drug discovery for SYNGAP1 related disorders with @rarebasepbc. Thanks @JMGraglia and @SYNGAP1mom for all you do for the community!

Our #precisionmedicine platform Function identifies #drugrepurposing candidates that have the potential to target the root cause biology of rare genetic diseases. Discover how we identify these candidates based on common types of genetic variants: rarebase.org/post/how-does-…

Next week our CSO, Chris Moxham, PhD, will give a showcase talk titled “Accelerating a Path Forward for #RareDisease #DrugDiscovery” @PMWCintl on January 27, 2023 in Santa Clara, CA. We are excited to share our insights on scalable approaches for precision medicine #PMWC23

“These things don’t have to be lonely crusades, but they are. Everyone is on their own right now.” @onnofaber and @rarebasepbc are a mission to remake the dysfunctional rare disease research space. buff.ly/3CoXeuP